UA105201C2 - Застосування рекомбінантного альбуміну людини-гранулоцитарного колонієстимулюючого фактора людини для запобігання нейтропенії або лейкопенії - Google Patents
Застосування рекомбінантного альбуміну людини-гранулоцитарного колонієстимулюючого фактора людини для запобігання нейтропенії або лейкопеніїInfo
- Publication number
- UA105201C2 UA105201C2 UAA201109961A UAA201109961A UA105201C2 UA 105201 C2 UA105201 C2 UA 105201C2 UA A201109961 A UAA201109961 A UA A201109961A UA A201109961 A UAA201109961 A UA A201109961A UA 105201 C2 UA105201 C2 UA 105201C2
- Authority
- UA
- Ukraine
- Prior art keywords
- stimulating factor
- colony stimulating
- leukopenia
- granulocyte colony
- human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14544009P | 2009-01-16 | 2009-01-16 | |
| US14543609P | 2009-01-16 | 2009-01-16 | |
| PCT/US2010/021241 WO2010083439A2 (en) | 2009-01-16 | 2010-01-15 | Recombinant human albumin-human granulocyte colony stimulating factor for the prevention of neutropenia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA105201C2 true UA105201C2 (uk) | 2014-04-25 |
Family
ID=42260335
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201109961A UA105201C2 (uk) | 2009-01-16 | 2010-01-15 | Застосування рекомбінантного альбуміну людини-гранулоцитарного колонієстимулюючого фактора людини для запобігання нейтропенії або лейкопенії |
| UAA201109963A UA103221C2 (uk) | 2009-01-16 | 2010-01-15 | Стабільний склад рекомбінантного альбуміну людини-гранулоцитарного колонієстимулюючого фактора людини |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201109963A UA103221C2 (uk) | 2009-01-16 | 2010-01-15 | Стабільний склад рекомбінантного альбуміну людини-гранулоцитарного колонієстимулюючого фактора людини |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US20100227818A1 (enExample) |
| EP (2) | EP2387420A2 (enExample) |
| JP (2) | JP2012515222A (enExample) |
| KR (2) | KR20110132327A (enExample) |
| CN (2) | CN102378635A (enExample) |
| AU (2) | AU2010204552B2 (enExample) |
| BR (2) | BRPI1004940A2 (enExample) |
| CA (2) | CA2749786A1 (enExample) |
| EA (2) | EA023344B1 (enExample) |
| IL (2) | IL214052A0 (enExample) |
| MX (2) | MX2011007583A (enExample) |
| NZ (2) | NZ594055A (enExample) |
| SG (3) | SG172941A1 (enExample) |
| UA (2) | UA105201C2 (enExample) |
| WO (2) | WO2010083439A2 (enExample) |
| ZA (1) | ZA201105171B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1004940A2 (pt) * | 2009-01-16 | 2018-06-19 | Teva Pharma | composição farmacêutica |
| EP2384759A1 (en) | 2010-05-06 | 2011-11-09 | Suomen Punainen Risti Veripalvelu | Sulphated hyaluronic acid in combination with G-CSF for use in mobilising blood stem cells |
| ES2545411T5 (es) * | 2010-06-07 | 2024-04-05 | Amgen Inc | Dispositivo de administración de fármaco |
| CN102628869B (zh) * | 2012-04-19 | 2014-04-02 | 上海蓝怡科技有限公司 | 提高甲胎蛋白抗体冻干稳定性的制剂 |
| EP2945703A4 (en) * | 2013-01-15 | 2016-08-31 | Teva Pharma | ALBU-BCHE FORMULATIONS, PREPARATION THEREOF AND USES THEREOF |
| US20140271538A1 (en) | 2013-03-15 | 2014-09-18 | Teva Pharmaceutical Industries Ltd. | Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor for the Prevention of Neutropenia in Pediatric Patients |
| MA40904A (fr) * | 2014-11-03 | 2017-09-12 | Hygeia Tech Inc | Compositions d'ester de phorbol et procédés pour traiter ou réduire la durée d'une cytopénie |
| HK1249052A1 (zh) | 2015-03-06 | 2018-10-26 | BeyondSpring Pharmaceuticals Inc. | 治疗与ras突变相关的癌症的方法 |
| BE1023343B1 (nl) * | 2015-05-20 | 2017-02-09 | Mycartis Nv | Opslagbuffer |
| EP3334726B1 (en) | 2015-07-13 | 2022-03-16 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
| JP2018522030A (ja) * | 2015-07-30 | 2018-08-09 | エンドール テクノロジーズ, エス.エレ.Endor Technologies, S.L. | 膵癌又は大腸癌の治療用コロニー刺激因子 |
| US10912748B2 (en) | 2016-02-08 | 2021-02-09 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| CN109475524A (zh) | 2016-06-06 | 2019-03-15 | 万春药业公司 | 用于减少中性粒细胞减少症的组合物和方法 |
| CN106222221A (zh) * | 2016-08-05 | 2016-12-14 | 山东科兴生物制品有限公司 | 制备重组人粒细胞刺激因子原液的纯化方法 |
| EP3544658B1 (en) | 2016-11-22 | 2024-07-03 | LTS Device Technologies Ltd | Apparatus for delivering a therapeutic substance |
| WO2018129381A1 (en) | 2017-01-06 | 2018-07-12 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| KR20190109479A (ko) | 2017-02-01 | 2019-09-25 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 호중구감소증의 감소 방법 |
| WO2018187786A1 (en) * | 2017-04-07 | 2018-10-11 | La Jolla Institute For Allergy And Immunology | Unipotent neutrophil progenitor cells, methods of preparation, and uses thereof |
| CN109420159A (zh) * | 2017-08-23 | 2019-03-05 | 江苏泰康生物医药有限公司 | 一种重组蛋白药物的新型稳定制剂 |
| WO2019147615A1 (en) | 2018-01-24 | 2019-08-01 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing thrombocytopenia via the administration of plinabulin |
| BR112020015758A2 (pt) * | 2018-02-01 | 2020-12-08 | Beyondspring Pharmaceuticals, Inc. | Composição e método para reduzir neutropenia induzida por quimioterapia através da administração de plinabulina e agente de g-csf |
| US11583633B2 (en) | 2018-04-03 | 2023-02-21 | Amgen Inc. | Systems and methods for delayed drug delivery |
| EP3632487B1 (en) | 2018-10-05 | 2024-06-12 | LTS Device Technologies Ltd | Triggering sequence |
| CN111383745A (zh) * | 2018-12-29 | 2020-07-07 | 医渡云（北京）技术有限公司 | 计算机数据处理方法、装置、存储介质及设备 |
| US11267858B2 (en) | 2019-05-31 | 2022-03-08 | Spectrum Pharmaceuticals, Inc. | Methods of treatment using G-CSF protein complex |
| US11684655B2 (en) * | 2019-05-31 | 2023-06-27 | Spectrum Pharmaceuticals, Inc. | Methods of treating neutorpenia using G-CSF protein complex |
| CN112316120A (zh) * | 2019-08-05 | 2021-02-05 | 天津派格生物技术有限公司 | 使用低动员型g-csf有效且安全治疗粒细胞减少症的方法 |
| WO2021112654A1 (en) * | 2019-12-05 | 2021-06-10 | Hanmi Pharm. Co., Ltd. | Methods of treating chemotherapy or radiotherapy induced neutropenia |
| KR102485892B1 (ko) * | 2020-04-09 | 2023-01-09 | 주식회사 에이프릴바이오 | 고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도 |
| BR112022020256A2 (pt) | 2020-04-09 | 2023-01-03 | Aprilbio Co Ltd | anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, ácido nucleico, vetor de expressão, célula, composição, uso da composição e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo |
| CN111751552B (zh) * | 2020-06-18 | 2022-09-16 | 广州市伊川生物科技有限公司 | 一种缺血修饰白蛋白测定试剂盒及其使用方法 |
| KR102375269B1 (ko) * | 2021-01-27 | 2022-03-17 | 한미약품 주식회사 | 단백질 액상 제제 및 이의 제조방법 |
| EP4319751A4 (en) | 2021-04-09 | 2025-02-26 | Beyondspring Pharmaceuticals, Inc. | THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS |
| US11723955B1 (en) * | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2052712T3 (es) | 1987-04-09 | 1994-07-16 | Delta Biotechnology Ltd | Vector de levadura. |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| FR2686900B1 (fr) | 1992-01-31 | 1995-07-21 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant. |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| DE4242863A1 (de) * | 1992-12-18 | 1994-06-23 | Boehringer Mannheim Gmbh | Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF |
| DE19549232C2 (de) * | 1995-12-20 | 1998-05-20 | Boehringer Mannheim Gmbh | Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern |
| US7321023B2 (en) * | 1997-11-07 | 2008-01-22 | Incyte Corporation | SP16 protein |
| KR100389726B1 (ko) * | 1998-03-06 | 2003-06-27 | 쥬가이 세이야쿠 가부시키가이샤 | 안정한 과립구 콜로니-자극 인자 함유 제제 |
| US6831158B2 (en) * | 2000-01-10 | 2004-12-14 | Maxygen Holdings Ltd. | G-CSF conjugates |
| US6555660B2 (en) * | 2000-01-10 | 2003-04-29 | Maxygen Holdings Ltd. | G-CSF conjugates |
| US6926898B2 (en) | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| AU2002302814A1 (en) * | 2001-06-08 | 2002-12-23 | Powderject Vaccines, Inc. | Spray freeze-dried compositions |
| WO2005003296A2 (en) | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CA2841097A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin and g-csf fusion proteins |
| AU2003210806A1 (en) | 2002-03-05 | 2003-09-22 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| CN1241946C (zh) | 2002-07-01 | 2006-02-15 | 美国福源集团 | 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白 |
| WO2004082640A2 (en) * | 2003-03-19 | 2004-09-30 | New Century Pharmaceuticals, Inc. | Human serum albumin conjugates with therapeutic compounds |
| US6972332B1 (en) * | 2004-05-20 | 2005-12-06 | Acura Pharmaceuticals, Inc. | Process for the production of opiates |
| CA2618476A1 (en) | 2005-08-12 | 2007-02-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CA2584927C (en) * | 2006-04-13 | 2011-02-08 | Wix Filtration Corp. | A body for actuating a standpipe of a replaceable filter element |
| JP2008146587A (ja) * | 2006-12-13 | 2008-06-26 | Sony Corp | 表示装置、表示プログラム、表示方法、画像提供装置、画像提供プログラム、画像提供方法及び記録媒体 |
| BRPI1004940A2 (pt) * | 2009-01-16 | 2018-06-19 | Teva Pharma | composição farmacêutica |
-
2010
- 2010-01-15 BR BRPI1004940A patent/BRPI1004940A2/pt not_active IP Right Cessation
- 2010-01-15 AU AU2010204552A patent/AU2010204552B2/en not_active Ceased
- 2010-01-15 CN CN2010800127233A patent/CN102378635A/zh active Pending
- 2010-01-15 CA CA2749786A patent/CA2749786A1/en not_active Abandoned
- 2010-01-15 UA UAA201109961A patent/UA105201C2/uk unknown
- 2010-01-15 JP JP2011546399A patent/JP2012515222A/ja active Pending
- 2010-01-15 SG SG2011050366A patent/SG172941A1/en unknown
- 2010-01-15 SG SG2011050358A patent/SG172940A1/en unknown
- 2010-01-15 EP EP10701082A patent/EP2387420A2/en not_active Withdrawn
- 2010-01-15 MX MX2011007583A patent/MX2011007583A/es active IP Right Grant
- 2010-01-15 US US12/688,754 patent/US20100227818A1/en not_active Abandoned
- 2010-01-15 EA EA201190080A patent/EA023344B1/ru not_active IP Right Cessation
- 2010-01-15 CA CA2749802A patent/CA2749802C/en not_active Expired - Fee Related
- 2010-01-15 WO PCT/US2010/021241 patent/WO2010083439A2/en not_active Ceased
- 2010-01-15 CN CN201080012749.8A patent/CN102395379B/zh not_active Expired - Fee Related
- 2010-01-15 EA EA201190079A patent/EA201190079A1/ru unknown
- 2010-01-15 US US12/688,655 patent/US8323634B2/en not_active Expired - Fee Related
- 2010-01-15 SG SG2014003073A patent/SG196821A1/en unknown
- 2010-01-15 AU AU2010204547A patent/AU2010204547B2/en not_active Ceased
- 2010-01-15 NZ NZ594055A patent/NZ594055A/xx not_active IP Right Cessation
- 2010-01-15 JP JP2011546396A patent/JP5753095B2/ja not_active Expired - Fee Related
- 2010-01-15 BR BRPI1005159A patent/BRPI1005159A2/pt not_active IP Right Cessation
- 2010-01-15 WO PCT/US2010/021235 patent/WO2010083434A2/en not_active Ceased
- 2010-01-15 MX MX2011007582A patent/MX2011007582A/es active IP Right Grant
- 2010-01-15 UA UAA201109963A patent/UA103221C2/uk unknown
- 2010-01-15 NZ NZ594056A patent/NZ594056A/xx not_active IP Right Cessation
- 2010-01-15 KR KR1020117018162A patent/KR20110132327A/ko not_active Ceased
- 2010-01-15 EP EP10700685A patent/EP2387419A2/en not_active Withdrawn
- 2010-01-15 KR KR1020117018153A patent/KR20110132326A/ko not_active Ceased
-
2011
- 2011-07-12 IL IL214052A patent/IL214052A0/en unknown
- 2011-07-12 IL IL214051A patent/IL214051A0/en unknown
- 2011-07-13 ZA ZA2011/05171A patent/ZA201105171B/en unknown
-
2012
- 2012-10-25 US US13/660,915 patent/US8993519B2/en not_active Expired - Fee Related
-
2014
- 2014-12-18 US US14/574,553 patent/US20150202268A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011007582A (es) | Nuevas formulaciones estables de proteina de fusion recombinante de albumina humana-factor humano de estimulacion de colonias de granulocitos. | |
| EP3211001A3 (en) | Superagonists and antagonists of interleukin-2 | |
| WO2009133137A3 (en) | Pegylated recombinant human growth hormone compounds | |
| EP3321276A3 (en) | Fusion proteins for treating metabolic disorders | |
| ATE466085T1 (de) | Protease-resistente modifizierte interferon alpha polypeptide | |
| ATE540973T1 (de) | Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung | |
| BRPI0618488A2 (pt) | proteìnas de fusão de ìntron de fator de crescimento de hepatócito | |
| MX2012007318A (es) | Proteina de fusion de la region constante del anticuerpo-cd47 tetravalente para usarse en terapia. | |
| DK1317537T3 (da) | Sammensætninger og fremgangsmåder med G-CSF analoger | |
| IL188480A0 (en) | Glycosylated il-7, preparation and uses | |
| IN2012DN02981A (enExample) | ||
| DK2251353T3 (da) | Homogene fremstillinger af IL-29 | |
| NZ715014A (en) | Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients | |
| MX2010002557A (es) | Interferon alfa 2b modificado por glicol de polietileno, la preparacion y el uso del mismo. | |
| MXPA05008704A (es) | Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas. | |
| UA91820C2 (ru) | Терапевтическое применение вариантов хемокинов | |
| PH12021551372A1 (en) | Human alpha-galactosidase variants | |
| DE602004017148D1 (de) | S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung | |
| PH12016500708A1 (en) | Recombinant glycoproteins and uses thereof | |
| WO2014147489A3 (en) | Recombinant human albumin-human granulocyte colony stimulating factor for the prevention of neutropenia in pediatric patients | |
| DE602004030617D1 (de) | Rekombinante anti-cd64-eta' immunotoxine | |
| WO2012031115A3 (en) | In vivo anti-tumor activity of a recombinant il-7/hgf(beta) hybrid cytokine and associated methods of use | |
| PL363501A1 (en) | Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity | |
| TW200722104A (en) | Low-toxicity, long-circulating human interferon-α analogs | |
| EA200801077A1 (ru) | Антагонисты взаимодействия pf4 и rantes |